ReviewThe World Allergy Organization journal2020
Acute asthma management during SARS-CoV2-pandemic 2020.
Review in The World Allergy Organization journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 52 citations in OpenAlex.
- A randomised controlled trial comparing epinephrine and dexamethasone to placebo in the treatment of infants with bronchiolitis: the Bronchiolitis in Infants PlaceboERJ open research · 2025Article
- Carbon emissions from the increasing use of inhaled corticosteroid-LABA medications: a primary care used case from Singapore.NPJ primary care respiratory medicine · 2025Article
- Utility of biomarkers in the diagnosis and monitoring of asthmatic children.The World Allergy Organization journal · 2023Review
- Pathogenic role of cytokines in COVID-19, its association with contributing co-morbidities and possible therapeutic regimens.Inflammopharmacology · 2022Review
- Primary Care Management of Asthma Exacerbations or Attacks: Impact of the COVID-19 Pandemic.Advances in therapy · 2022Article
- Childhood asthma outcomes during the COVID-19 pandemic: Findings from the PeARL multi-national cohort.Allergy · 2021Article
- Emerging treatment strategies for COVID-19 infection.Clinical and experimental medicine · 2021Review
- Containment of procedure-associated aerosols by an extractor tent: effect on nebulized drug particle dispersal.The Journal of hospital infection · 2021Article
- Global Quality Statements on Reliever Use in Asthma in Adults and Children Older than 5 Years of Age.Advances in therapy · 2021Article
- Allergy and coronavirus disease (COVID-19) international survey: Real-life data from the allergy community during the pandemic.The World Allergy Organization journal · 2021Article
- Management of Anaphylaxis During the SARS-CoV-2 Pandemic.Current treatment options in allergy · 2021Review
- Expert Opinion on Restoration of Pediatric Pulmonology Services During the SARS-CoV-2 Pandemic.Indian pediatrics · 2020Article
- Impact of COVID-19 on Pediatric Asthma: Practice Adjustments and Disease Burden.The journal of allergy and clinical immunology. In practice · 2020Article
- Approach to childhood asthma in the era of COVID-19: The official statement endorsed by the Saudi Pediatric Pulmonology Association (SPPA).International journal of pediatrics & adolescent medicine · 2020Article
- Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review.Respiratory medicine · 2020Review
- COVID-19 and allergy.Asia Pacific allergy · 2020Article
- [Recommendations for therapy in pandemic times: Acting (and treating) correctly under pressure to act].Notfall & rettungsmedizin · 2020Article
- Asthma and COVID-19: In Defense of Evidence-Based SABA.Journal of asthma and allergy · 2020Article
- Asthma and the Coronavirus Disease 2019 Pandemic: A Literature Review.International archives of allergy and immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 13 institutions in 10 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe current COVID-19 pandemic has changed many medical practices in order to provide additional protection to both our patients and healthcare providers. In many cases this includes seeing patients through electronic means such as telehealth or telephone rather than seeing them in person. Asthma exacerbations cannot always be treated in this way. PROBLEM: Current emergency unit asthma guidelines recommend bronchodilators be administered by metered dose inhaler (MDI) and spacer for mild-moderate asthma and include it as a choice even in severe asthma, but many emergency units continue to prefer nebulised therapy for patients who urgently require beta-agonists. The utilization of nebulised therapy potentially increases the risk of aerosolization of the coronavirus. Since nosocomial transmission of respiratory pathogens is a major threat in the context of the SARS-CoV-2 pandemic, use of nebulised therapy is of even greater concern due to the potential increased risk of infection spread to nearby patients and healthcare workers. PRACTICAL IMPLICATIONS: We propose a risk stratification plan that aims to avoid nebulised therapy, when possible, by providing an algorithm to help better delineate those who require nebulised therapy. Protocols that include strategies to allow flexibility in using MDIs rather than nebulisers in all but the most severe patients should help mitigate this risk of aerosolised infection transmission to patients and health care providers. Furthermore, expedient treatment of patients with high dose MDI therapy augmented with more rapid initiation of systemic therapy may help ensure patients are less likely to deteriorate to the stage where nebulisers are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.